We are proud to announce significant advancements in our intellectual property portfolio during 2023, solidifying our position as a leading innovator in musculoskeletal rehabilitation technology.

The Capacitive Angular Displacement Sensor, pivotal to the transformative KIMIA Monitoring System, secured a worldwide license (except for US, UK, Canada). This critical milestone empowers rehabilitation therapists across the globe with Kinexcs’ unparalleled, data-driven approach to precise joint movement measurement.

A granted patent safeguards the Angular Displacement Sensor Calibration Technique, ensuring sensor accuracy and reliable data for patient benefit. Recognizing the global value of this innovation, we have filed corresponding patent applications in key markets like North America, Europe, and India.

Kinexcs’ commitment to the future of musculoskeletal rehabilitation is evident in our strategic patent filings. A provisional patent in the USA protects “A SYSTEM AND METHOD FOR ASSESSMENT AND CORRECTION OF JOINT RANGE OF MOTION”, further demonstrating the company’s dedication to individualized therapy plans. Additionally, the provisional patent filing for “A novel system and method for scheduling and delivering intervention to patients with musculoskeletal conditions via tactile feedback” underscores our exploration of novel therapeutic approaches.

Beyond safeguarding our technological advancements, we solidified our brand identity in 2023 by securing trademarks for both “Kinexcs” (word and logo) and “KIMIA”. This ensures clear brand differentiation and strengthens the company’s position within the healthcare landscape.

Kinexcs’ robust IP portfolio is a testament to our unwavering commitment to innovation and a resolute focus on improving patient outcomes through cutting-edge technology. The company is not simply a pioneer in musculoskeletal rehabilitation; it is an architect of a future where personalized, data-driven therapy enables and empowers people for mobility and a better quality of life.